Table 1:
Baseline characteristics of all randomized subjects with dual x-ray absorptiometry (DXA) test
| Placebo | Isoflavone | |||
|---|---|---|---|---|
| Variables †, ‡ | n0 | Means ± SD; % | n1 | Means ± SD; % |
| Consent Age (years) | 96 | 37.35 ± 3.43 | 98 | 37.58 ± 2.96 |
| Weight (kg) | 96 | 75.06 ± 17.50 | 98 | 73.46 ± 16.70 |
| Race/ethnicity (%) | 96 | 49.48 | 96 | 50.52 |
| Hispanic | 39 | 44.04 | 50 | 44.96 |
| African American | 12 | 12.89 | 14 | 13.13 |
| White | 45 | 39.09 | 34 | 39.91 |
| Height (cm) | 96 | 160.10 ± 6.01 | 98 | 160.70 ± 7.67 |
| BMI (kg/m2) | 96 | 29.23 ± 6.38 | 98 | 28.45 ± 6.08 |
| Waist circumference (cm) | 95 | 90.84 ± 13.92 | 98 | 89.51 ± 13.18 |
| Hip circumference (cm) | 95 | 109.10 ± 13.07 | 98 | 108.10 ± 11.46 |
| Waist-to-hip | 95 | 0.83 ± 0.06 | 98 | 0.83 ± 0.06 |
| Riboflavin (μg/mL) | 91 | 10−3 ± 10−3 | 93 | 10−3 ± 10−3 |
| Daidzein (μg/mL) | 90 | 10−3 ± 4×10−4 | 89 | 10−3 ± 10−3 |
| Genistein (μg/mL) | 90 | 10−3 ± 10−3 | 89 | 10−3 ± 10−3 |
| Riboflavin (mg/h) | 91 | 0.05 ± 0.08 | 93 | 0.06 ± 0.12 |
| Daidzein (mg/h) | 90 | 0.06 ± 0.03 | 89 | 0.07 ± 0.04 |
| Genistein (mg/h) | 90 | 0.08 ± 0.05 | 89 | 0.08 ± 0.04 |
| Total protein (g/dL) | 96 | 7.53 ± 0.51 | 97 | 7.51 ± 0.45 |
| Albumin (g/dL) | 96 | 4.27 ± 0.34 | 98 | 4.28 ± 0.26 |
| Alkaline phosphatase (U/L) | 96 | 75.32 ± 18.33 | 98 | 72.07 ± 18.97 |
| Calcium (mg/dL) | 96 | 9.01 ± 0.35 | 98 | 9.05 ± 0.28 |
| Creatinine (mg/dL) | 96 | 0.75 ± 0.11 | 98 | 0.76 ± 0.12 |
| Potassium (mEq/L) | 96 | 4.04 ± 0.22 | 98 | 4.07 ± 0.24 |
| Sodium (mEq/L) | 96 | 140.50 ± 1.48 | 98 | 140.70 ± 1.50 |
| From DXA tests | ||||
| Fat (%) | 96 | 37.40 ± 6.92 | 98 | 36.31 ± 6.64 |
| Lean body mass (kg) | 96 | 44.12 ± 7.28 | 98 | 43.95 ± 7.08 |
| Fat body mass (kg) | 96 | 29.07 ± 11.40 | 98 | 27.57 ± 10.61 |
| Lean bone mineral content (kg) | 96 | 46.20 ± 7.47 | 98 | 46.05 ± 7.24 |
| Whole body bone mineral content (kg) | 96 | 2.08 ± 0.29 | 98 | 2.11 ± 0.28 |
| Hip bone mineral content (g) | 96 | 33.38 ± 6.17 | 98 | 33.82 ± 5.15 |
| Spine bone mineral content (g) | 96 | 60.32 ± 9.04 | 98 | 61.26 ± 9.87 |
| Hip bone mineral density (g/cm2) | 96 | 1.00 ± 0.13 | 98 | 1.01 ± 0.12 |
| Spine bone mineral density (g/cm2) | 96 | 1.06 ± 0.11 | 98 | 1.06 ± 0.11 |
| Whole body bone mineral density (g/cm2) | 96 | 1.07 ± 0.09 | 98 | 1.08 ± 0.09 |
| Study visit (number) | 96 | 8.73 ± 2.93 | 98 | 8.80 ± 3.08 |
A total of 197 subjects were randomized into placebo and isoflavone, respectively. Two placebo and one isoflavone subjects had breast images but no DXA tests, resulting 194 subjects in analysis.
†
Except for race/ethnicity and study visits, all descriptive analyses on numerical variables were averages of 4 baseline visits. Study visit was average number of all baseline and follow-up visits. For numerical variables, the corresponding means and standard deviations (SDs) were stratified by groups. For categorical variable, percentages were presented.
‡
All P > .05 for two group comparisons.